Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Core Insights - Xeris Biopharma Holdings (NASDAQ: XERS) has experienced a significant stock price increase of over 45% in the past month, primarily due to impressive Q2 2025 results [1] Financial Performance - The company's revenue for Q2 2025 has shown a notable rise, contributing to the bullish trend in its stock price [1]